SG11201909676WA - Treatment of her2 positive cancers - Google Patents
Treatment of her2 positive cancersInfo
- Publication number
- SG11201909676WA SG11201909676WA SG11201909676WA SG11201909676WA SG 11201909676W A SG11201909676W A SG 11201909676WA SG 11201909676W A SG11201909676W A SG 11201909676WA SG 11201909676W A SG11201909676W A SG 11201909676WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- tucatinib
- trastuzumab
- suite
- pct
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 abstract 4
- 229950003463 tucatinib Drugs 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 229960000575 trastuzumab Drugs 0.000 abstract 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 239000000783 alginic acid Substances 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491872P | 2017-04-28 | 2017-04-28 | |
| PCT/US2018/029899 WO2018201016A1 (en) | 2017-04-28 | 2018-04-27 | Treatment of her2 positive cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909676WA true SG11201909676WA (en) | 2019-11-28 |
Family
ID=62165692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909676W SG11201909676WA (en) | 2017-04-28 | 2018-04-27 | Treatment of her2 positive cancers |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11207324B2 (enExample) |
| EP (1) | EP3615067A1 (enExample) |
| JP (2) | JP7328151B2 (enExample) |
| KR (1) | KR102845148B1 (enExample) |
| CN (1) | CN111032082B (enExample) |
| AU (2) | AU2018258663B2 (enExample) |
| BR (1) | BR112019022280A2 (enExample) |
| CA (1) | CA3060407A1 (enExample) |
| EA (1) | EA201992573A1 (enExample) |
| MA (1) | MA49059A (enExample) |
| SG (1) | SG11201909676WA (enExample) |
| WO (1) | WO2018201016A1 (enExample) |
| ZA (1) | ZA201907225B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111032082B (zh) * | 2017-04-28 | 2025-01-07 | 西雅图基因公司 | Her2阳性癌症的治疗 |
| TW202042820A (zh) * | 2019-01-28 | 2020-12-01 | 美商西雅圖遺傳學股份有限公司 | 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 |
| WO2020251556A1 (en) * | 2019-06-11 | 2020-12-17 | Io Therapeutics, Inc. | Use of an rxr agonist in treating her2+ cancers |
| KR20220086627A (ko) * | 2019-10-21 | 2022-06-23 | 시아겐 인크. | 카페시타빈 및 트라스투주맙과 조합으로 투카티닙을 사용하여 her2 양성 유방암을 치료하는 방법 |
| US20220387618A1 (en) * | 2019-11-15 | 2022-12-08 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| IL298538A (en) * | 2020-05-29 | 2023-01-01 | Seagen Inc | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy |
| WO2022026510A1 (en) * | 2020-07-29 | 2022-02-03 | Seagen Inc. | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist |
| US20230372342A1 (en) * | 2020-09-28 | 2023-11-23 | Seagen Inc. | Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Pharmaceutical compositions of a her2/neu antibody and use of the same |
| US11526994B1 (en) * | 2021-09-10 | 2022-12-13 | Neosoma, Inc. | Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images |
| WO2024183622A1 (zh) * | 2023-03-03 | 2024-09-12 | 盛禾(中国)生物制药有限公司 | 一种抗her2抗体在制备治疗癌症的药物中的用途 |
| WO2025132522A1 (en) | 2023-12-20 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| CA2129514A1 (en) | 1992-03-12 | 1993-09-16 | M. Amin Khan | Controlled released acth containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| JP4828421B2 (ja) | 2003-08-14 | 2011-11-30 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
| US20100063074A1 (en) | 2004-06-03 | 2010-03-11 | Berger Mark S | Cancer Treatment Method |
| DK1971601T3 (da) | 2005-11-15 | 2010-02-08 | Array Biopharma Inc | N4-phenyl-quinazolin-4-aminderivater og beslægtede forbindelser som ERBB Type 1-receptortyrosinkinase-inhibitorer til behandling af hyperproliferative sygdomme |
| WO2009042618A1 (en) | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| MY166445A (en) | 2008-03-18 | 2018-06-27 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use |
| NO2719708T3 (enExample) * | 2009-11-13 | 2018-03-24 | ||
| SG194609A1 (en) * | 2011-05-19 | 2013-12-30 | Lab Corp America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
| WO2013056108A2 (en) | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Solid dispersion |
| EP2766363A1 (en) | 2011-10-14 | 2014-08-20 | Array Biopharma, Inc. | Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them |
| KR102490961B1 (ko) | 2012-03-23 | 2023-01-19 | 어레이 바이오파마 인크. | 뇌암의 치료 |
| WO2016011328A1 (en) * | 2014-07-17 | 2016-01-21 | Baker Cheryl | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent |
| US10702527B2 (en) * | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN109952306A (zh) * | 2016-04-19 | 2019-06-28 | 加利福尼亚大学董事会 | ErbB抑制剂及其用途 |
| CN111032082B (zh) | 2017-04-28 | 2025-01-07 | 西雅图基因公司 | Her2阳性癌症的治疗 |
| US20210239702A1 (en) | 2018-06-14 | 2021-08-05 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies |
| TW202042820A (zh) | 2019-01-28 | 2020-12-01 | 美商西雅圖遺傳學股份有限公司 | 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法 |
| KR20220086627A (ko) | 2019-10-21 | 2022-06-23 | 시아겐 인크. | 카페시타빈 및 트라스투주맙과 조합으로 투카티닙을 사용하여 her2 양성 유방암을 치료하는 방법 |
| US20220387618A1 (en) | 2019-11-15 | 2022-12-08 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| MX2022011160A (es) | 2020-03-11 | 2022-10-18 | Seagen Inc | Metodos de tratar canceres mutantes de her2 con tucatinib. |
-
2018
- 2018-04-27 CN CN201880043831.3A patent/CN111032082B/zh active Active
- 2018-04-27 KR KR1020197035001A patent/KR102845148B1/ko active Active
- 2018-04-27 MA MA049059A patent/MA49059A/fr unknown
- 2018-04-27 BR BR112019022280A patent/BR112019022280A2/pt unknown
- 2018-04-27 JP JP2019558369A patent/JP7328151B2/ja active Active
- 2018-04-27 SG SG11201909676W patent/SG11201909676WA/en unknown
- 2018-04-27 US US16/607,850 patent/US11207324B2/en active Active
- 2018-04-27 WO PCT/US2018/029899 patent/WO2018201016A1/en not_active Ceased
- 2018-04-27 AU AU2018258663A patent/AU2018258663B2/en active Active
- 2018-04-27 EP EP18724716.8A patent/EP3615067A1/en active Pending
- 2018-04-27 CA CA3060407A patent/CA3060407A1/en active Pending
- 2018-04-27 EA EA201992573A patent/EA201992573A1/ru unknown
-
2019
- 2019-10-30 ZA ZA2019/07225A patent/ZA201907225B/en unknown
-
2021
- 2021-11-18 US US17/530,265 patent/US11666572B2/en active Active
-
2022
- 2022-09-28 AU AU2022241509A patent/AU2022241509B2/en active Active
-
2023
- 2023-04-26 US US18/139,653 patent/US12048698B2/en active Active
- 2023-08-03 JP JP2023126666A patent/JP2023145689A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA49059A (fr) | 2021-03-24 |
| JP2020517696A (ja) | 2020-06-18 |
| KR102845148B1 (ko) | 2025-08-20 |
| US11666572B2 (en) | 2023-06-06 |
| CA3060407A1 (en) | 2018-11-01 |
| CN111032082B (zh) | 2025-01-07 |
| US20200188401A1 (en) | 2020-06-18 |
| BR112019022280A2 (pt) | 2020-05-19 |
| AU2018258663A1 (en) | 2019-11-14 |
| ZA201907225B (en) | 2023-11-29 |
| AU2022241509A1 (en) | 2022-10-27 |
| US12048698B2 (en) | 2024-07-30 |
| WO2018201016A1 (en) | 2018-11-01 |
| US20220168303A1 (en) | 2022-06-02 |
| JP2023145689A (ja) | 2023-10-11 |
| EA201992573A1 (ru) | 2020-04-06 |
| US20230390290A1 (en) | 2023-12-07 |
| AU2022241509B2 (en) | 2025-02-20 |
| JP7328151B2 (ja) | 2023-08-16 |
| EP3615067A1 (en) | 2020-03-04 |
| US11207324B2 (en) | 2021-12-28 |
| AU2018258663B2 (en) | 2022-08-04 |
| CN111032082A (zh) | 2020-04-17 |
| KR20200014298A (ko) | 2020-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909676WA (en) | Treatment of her2 positive cancers | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201906543RA (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
| SG11201905622VA (en) | Subcutaneous her2 antibody formulations | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201808913WA (en) | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201908790PA (en) | Glucocorticoid receptor modulators to treat cervical cancer | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201903431SA (en) | Sstr-targeted conjugates and particles and formulations thereof | |
| SG11201909552VA (en) | Combination therapy for prostate cancer | |
| SG11201908788YA (en) | Combinations of chk1- and wee1 - inhibitors | |
| SG11201909466RA (en) | Human anti-semaphorin 4d antibody |